AstraZeneca, Rigel sign license agreement for asthma therapy
Rigel’s R256 inhaled JAK inhibitor, which was shown to inhibit IL-13 and IL-4 signaling, is being investigated as a treatment for moderate to severe chronic asthma. R256 demonstrated
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.